The main objective of Xpop is to develop new sound and rigorous methods for statistical modeling in the field of biology and life sciences.
These methods for modeling include statistical methods of estimation, model diagnostics, model building and model selection as well as methods for numerical models (systems of ordinary and partial differential equations).
Historically, the key area where these methods have been used is population pharmacokinetics.
However, the framework is currently being extended to sophisticated numerical models in the contexts of viral dynamics, glucose-insulin processes, tumor growth, precision medicine, spectrometry, intracellular processes, etc.

Furthermore, an important aim of Xpop is to transfer the methods developed into software packages so that they can be used in everyday practice.

Mathematical models that characterize complex biological phenomena are defined by systems of ordinary differential equations when dealing with dynamical systems that evolve with respect to time, or by partial differential equations when there is a spatial component in the model. Also, it is sometimes useful to integrate a stochastic aspect into the dynamical system in order to model stochastic intra-individual variability.

In order to use such methods, we must deal with complex numerical difficulties, generally related to resolving the systems of differential equations. Furthermore, to be able to check the quality of a model (i.e. its descriptive and predictive performances), we require data. The statistical aspect of the model is thus critical in how it takes into account different sources of variability and uncertainty, especially when data come from several individuals and we are interested in characterizing the inter-subject variability. Here, the tools of reference are mixed-effects models.

Confronted with such complex modeling problems, one of the goals of Xpop is to show the importance of combining numerical, statistical and stochastic approaches.

Linear mixed-effects models have been well-used in statistics for a long time. They are a classical approach, essentially relying on matrix calculations in Gaussian models. Whereas a solid theoretical base has been developed for such models, nonlinear mixed-effects models (NLMEM) have received much less attention in the statistics community, even though they have been applied to many domains of interest. It has thus been the users of these models, such as pharmacometricians, who have taken them and developed methods, without really looking to develop a clean theoretical framework or understand the mathematical properties of the methods. This is why a standard estimation method in NLMEM is to linearize the model, and few people have been interested in understanding the properties of estimators obtained in this way.

Statisticians and pharmacometricians frequently realize the need to create bridges between these two communities. We are entirely convinced that this requires the development of new standards for population modeling that can be widely accepted by these various communities. These standards include the language used for encoding a model, the approach for representing a model and the methods for using it:

"Interfaces" is the defining characteristic of Xpop:

The interface between statistics, probability and numerical methods.
Mathematical modelling of complex biological phenomena require to combine numerical, stochastic and statistical approaches. The CMAP is therefore the right place to be for positioning the team at the interface between several mathematical disciplines.

The interface between mathematics and the life sciences. The goal of Xpop is to bring the right answers to the right questions. These answers are mathematical tools (statistics, numerical methods, etc.), whereas the questions come from the life sciences (pharmacology, medicine, biology, etc.).
This is why the point of Xpop is not to take part in mathematical projects only, but also pluridisciplinary ones.

The interface between mathematics and software development. The development of new methods is the main activity of Xpop. However, new methods are only useful if they end up being implemented in a software tool. On one hand, a strong partnership with Lixoft (the spin-off company who continue developing Monolix) allows us to maintaining this positioning. On the other hand, several members of the team are very active in the R community and develop widely used packages.

Mixed-effects models are statistical models with both fixed effects and random effects. They are well-adapted to situations where repeated measurements are made on the same individual/statistical unit.

Consider first a single subject

In a population framework, the vector of parameters

Then, the probabilistic model is the joint probability distribution

To define a model thus consists in defining precisely these two terms.

In most applications, the observed data

Here,

Function

The vector of individual parameters

The joint model of

Central to modern statistics is the use of probabilistic models. To relate these models to data requires the ability to calculate the probability of the observed data: the likelihood function, which is central to most statistical methods and provides a principled framework to handle uncertainty.

The emergence of computational statistics as a collection of powerful and general methodologies for carrying out likelihood-based inference made complex models with non-standard data accessible to likelihood, including hierarchical models, models with intricate latent structure, and missing data.

In particular, algorithms previously developed by Popix for mixed effects models, and today implemented in several software tools (especially Monolix) are part of these methods:

Computational statistics is an area which remains extremely active today. Recently, one can notice that the incentive for further improvements and innovation comes mainly from three broad directions: the high dimensional challenge, the quest for adaptive procedures that can eliminate the cumbersome process of tuning "by hand" the settings of the algorithms and the need for flexible theoretical support, arguably required by all recent developments as well as many of the traditional MCMC algorithms that are widely used in practice.

Working in these three directions is a clear objective for Xpop.

While these Monte Carlo algorithms have turned into standard tools over the past decade, they still face difficulties in handling less regular problems such as those involved in deriving inference for high-dimensional models. One of the main problems encountered when using MCMC in this challenging settings is that it is difficult to design a Markov chain that efficiently samples the state space of interest.

The Metropolis-adjusted Langevin algorithm (MALA) is a Markov chain Monte Carlo (MCMC) method for obtaining random samples from a probability distribution for which direct sampling is difficult. As the name suggests, MALA uses a combination of two mechanisms to generate the states of a random walk that has the target probability distribution as an invariant measure:

Informally, the Langevin dynamics drives the random walk towards regions of high probability in the manner of a gradient flow, while the Metropolis-Hastings accept/reject mechanism improves the mixing and convergence properties of this random walk.

Several extensions of MALA have been proposed recently by several authors, including fMALA (fast MALA), AMALA (anisotropic MALA), MMALA (manifold MALA), position-dependent MALA (PMALA), ...

MALA and these extensions have demonstrated to represent very efficient alternative for sampling from high dimensional distributions. We therefore need to adapt these methods to general mixed effects models.

The Stochastic Approximation Expectation Maximization (SAEM) algorithm has shown to be extremely efficient for maximum likelihood estimation in incomplete data models, and particularly in mixed effects models for estimating the population parameters. However, there are several practical situations for which extensions of SAEM are still needed:

High dimensional model: a complex physiological model may have a large number of parameters (in the order of 100). Then several problems arise:

Large number of covariates: the covariate model aims to explain part of the inter-patient variability of some parameters.
Classical methods for covariate model building are based on comparisons with respect to some criteria, usually derived from the likelihood (AIC, BIC), or some statistical test (Wald test, LRT, etc.). In other words, the modelling procedure requires two steps: first, all possible models are fitted using some estimation procedure (e.g. the SAEM algorithm) and the likelihood of each model is computed using a numerical integration procedure (e.g. Monte Carlo Importance Sampling); then, a model selection procedure chooses the "best" covariate model. Such a strategy is only possible with a reduced number of covariates, i.e., with a "small" number of models to fit and compare.

As an alternative, we are thinking about a Bayesian approach which consists of estimating simultaneously the covariate model and the parameters of the model in a single run. An (informative or uninformative) prior is defined for each model by defining a prior probability for each covariate to be included in the model. In other words, we extend the probabilistic model by introducing binary variables that indicate the presence or absence of each covariate in the model. Then, the model selection procedure consists of estimating and maximizing the conditional distribution of this sequence of binary variables. Furthermore, a probability can be associated to any of the possible covariate models.

This conditional distribution can be estimated using an MCMC procedure combined with the SAEM algorithm for estimating the population parameters of the model. In practice, such an approach can only deal with a limited number of covariates since the dimension of the probability space to explore increases exponentially with the number of covariates. Consequently, we would like to have methods able to find a small number of variables (from a large starting set) that influence certain parameters in populations of individuals. That means that, instead of estimating the conditional distribution of all the covariate models as described above, the algorithm should focus on the most likely ones.

Fixed parameters: it is quite frequent that some individual parameters of the model have no random component and are purely fixed effects. Then, the model may not belong to the exponential family anymore and the original version of SAEM cannot be used as it is.
Several extensions exist:

None of these methods always work correctly. Furthermore, what are the pros and cons of these methods is not clear at all. Then, developing a robust methodology for such model is necessary.

Convergence toward the global maximum of the likelihood: convergence of SAEM can strongly depend on thie initial guess when the observed likelihood has several local maxima. A kind of simulated annealing version of SAEM was previously developed and implemented in Monolix.
The method works quite well in most situations but there is no theoretical justification and choosing the settings of this algorithm (i.e. how the temperature decreases during the iterations) remains empirical.
A precise analysis of the algorithm could be very useful to better understand why it "works" in practice and how to optimize it.

Convergence diagnostic: Convergence of SAEM was theoretically demonstrated under very general hypothesis. Such result is important but of little interest in practice at the time to use SAEM in a finite amount of time, i.e. in a finite number of iterations.
Some qualitative and quantitative criteria should be defined in order to both optimize the settings of the algorithm, detect a poor convergence of SAEM and evaluate the quality of the results in order to avoid using them unwisely.

Defining an optimal strategy for model building is far from easy because a model is the assembled product of numerous components that need to been evaluated and perhaps improved: the structural model, residual error model, covariate model, covariance model, etc.

How to proceed so as to obtain the best possible combination of these components? There is no magic recipe but an effort will be made to provide some qualitative and quantitative criteria in order to help the modeller for building his model.

The strategy to take will mainly depend on the time we can dedicate to building the model and the time required for running it. For relatively simple models for which parameter estimation is fast, it is possible to fit many models and compare them. This can also be done if we have powerful computing facilities available (e.g., a cluster) allowing large numbers of simultaneous runs.

However, if we are working on a standard laptop or desktop computer, model building is a sequential process in which a new model is tested at each step. If the model is complex and requires significant computation time (e.g., when involving systems of ODEs), we are constrained to limit the number of models we can test in a reasonable time period. In this context, it also becomes important to carefully choose the tasks to run at each step.

Diagnostic tools are recognized as an essential method for model assessment in the process of model building. Indeed, the modeler needs to confront "his" model with the experimental data before concluding that this model is able to reproduce the data and before using it for any purpose, such as prediction or simulation for instance.

The objective of a diagnostic tool is twofold: first we want to check if the assumptions made on the model are valid or not ; then, if some assumptions are rejected, we want to get some guidance on how to improve the model.

As is the usual case in statistics, it is not because this "final" model has not been rejected that it is necessarily the "true" one. All that we can say is that the experimental data does not allow us to reject it. It is merely one of perhaps many models that cannot be rejected.

Model diagnostic tools are for the most part graphical, i.e., visual; we "see" when something is not right between a chosen model and the data it is hypothesized to describe. These diagnostic plots are usually based on the empirical Bayes estimates (EBEs) of the individual parameters and EBEs of the random effects: scatterplots of individual parameters versus covariates to detect some possible relationship, scatterplots of pairs of random effects to detect some possible correlation between random effects, plot of the empirical distribution of the random effects (boxplot, histogram,...) to check if they are normally distributed, ...

The use of EBEs for diagnostic plots and statistical tests is efficient with rich data, i.e. when a significant amount of information is available in the data for recovering accurately all the individual parameters. On the contrary, tests and plots can be misleading when the estimates of the individual parameters are greatly shrunk.

We propose to develop new approaches for diagnosing mixed effects models in a general context and derive formal and unbiased statistical tests for testing separately each feature of the model.

The ability to easily collect and gather a large amount of data from different sources can be seen as an opportunity to better understand many processes. It has already led to breakthroughs in several application areas. However, due to the wide heterogeneity of measurements and objectives, these large databases often exhibit an extraordinary high number of missing values. Hence, in addition to scientific questions, such data also present some important methodological and technical challenges for data analyst.

Missing values occur for a variety of reasons: machines that fail, survey participants who do not answer certain questions, destroyed or lost data, dead animals, damaged plants, etc. Missing values are problematic since most statistical methods can not be applied directly on a incomplete data. Many progress have been made to properly handle missing values. However, there are still many challenges that need to be addressed in the future, that are crucial for the users.

It is important to stress that missing data models are part of the general incomplete data models addressed by Xpop. Indeed, models with latent variables (i.e. non observed variables such as random effects in a mixed effects model), models with censored data (e.g. data below some limit of quantification) or models with dropout mechanism (e.g. when a subject in a clinical trial fails to continue in the study) can be seen as missing data models.

(joint project with the Traumabase group, AP-HP)

Major trauma is defined as any injury that endangers the life or the functional integrity of a person. It has been shown that management of major trauma based on standardized and protocol based care improves prognosis of patients especially for the two main causes of death in major trauma i.e., hemorrhage and traumatic brain injury.

However, evidence shows that patient management even in mature trauma systems often exceeds acceptable time frames, and despite existing guidelines deviations from protocol-based care are often observed. These deviations lead to a high variability in care and are associated with bad outcome such as inadequate hemorrhage control or delayed transfusion. Two main factors explain these observations. First, decision-making in trauma care is particularly demanding, because it requires rapid and complex decisions under time pressure in a very dynamic and multi-player environment characterized by high levels of uncertainty and stress. Second, being a complex and multiplayer process, trauma care is affected by fragmentation. Fragmentation is often the result of loss or deformation of information.

This disruptive influence prevents providers to engage with each other and commit to the care process.In order to respond to this challenge, our program has set the ambitious goal to develop a trauma decision support tool, the TraumaMatrix. The program aims to provide an integrative decision support and information management solution to clinicians for the first 24 hours of major trauma management. This program is divided into three steps.

Based on a detailed and high quality trauma database, Step 1 consists in developing the mathematical tools and models to predict trauma specific outcomes and decisions. This step raises considerable scientific and methodological challenges.

Step 2 will use these methods to apply them to develop in close cooperation with trauma care experts the decision support tool and develop a user friendly and ergonomic interface to be used by clinicians.

Step 3 will further develop the tool and interface and test in real-time its impact on clinician decision making and patient outcome.

(joint project with Dassault Systèmes)

Pharmacogenomics involves using an individual's genome to determine whether or not a particular therapy, or dose of therapy, will be effective. Indeed, people's reaction to a given drug depends on their physiological state and environmental factors, but also to their individual genetic make-up.

Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. While some advances in precision medicine have been made, the practice is not currently in use for most diseases.

Currently, in the traditional population approach, inter-individual variability in the reaction to drugs is modeled using covariates such as weight, age, sex, ethnic origin, etc. Genetic polymorphisms susceptible to modify pharmacokinetic or pharmacodynamic parameters are much harder to include, especially as there are millions of possible polymorphisms (and thus covariates) per patient.

The challenge is to determine which genetic covariates are associated to some PKPD parameters and/or implicated in patient responses to a given drug.

Another problem encountered is the dependence of genes, as indeed, gene expression is a highly regulated process. In cases where the explanatory variables (genomic variants) are correlated, Lasso-type methods for model selection are thwarted.

There is therefore a clear need for new methods and algorithms for the estimation, validation and selection of mixed effects models adapted to the problems of genomic medicine.

A target application of this project concerns the lung cancer.

EGFR (Epidermal Growth Factor Receptor) is a cell surface protein that binds to epidermal growth factor. We know that deregulation of the downstream signaling pathway of EGFR is involved in the development of lung cancers and several gene mutations responsible for this deregulation are known.

Our objective is to identify the variants responsible for the disruption of this pathway using a modelling approach. The data that should be available for developing such model are ERK (Extracellular signal–regulated kinases) phosphorylation time series, obtained from different genetic profiles.

The model that we aim to develop will describe the relationship between the parameters of the pathway and the genomic covariates, i.e. the genetic profile. Variants related to the pathway include: variants that modify the affinity binding of ligands to receptors, variants that modify the total amount of protein, variants that affect the catalytic site,...

(joint project with the Biochemistry lab of Ecole Polytechnique and Institut Curie)

In cancer, the most dreadful event is the formation of metastases that disseminate tumor cells throughout the organism. Cutaneous melanoma is a cancer, where the primary tumor can easily be removed by surgery. However, this cancer is of poor prognosis; because melanomas metastasize often and rapidly. Many melanomas arise from excessive exposure to mutagenic UV from the sun or sunbeds. As a consequence, the mutational burden of melanomas is generally high

RAC1 encodes a small GTPase that induces cell cycle progression and migration of melanoblasts during embryonic development. Patients with the recurrent P29S mutation of RAC1 have 3-fold increased odds at having regional lymph nodes invaded at the time of diagnosis. RAC1 is unlikely to be a good therapeutic target, since a potential inhibitor that would block its catalytic activity, would also lock it into the active GTP-bound state. This project thus investigates the possibility of targeting the signaling pathway downstream of RAC1.

Xpop is mainly involved in Task 1 of the project: Identifying deregulations and mutations of the ARP2/3 pathway in melanoma patients.

Association of over-expression or down-regulation of each marker with poor prognosis in terms of invasion of regional lymph nodes, metastases and survival, will be examined using classical univariate and multivariate analysis. We will then develop specific statistical models for survival analysis in order to associate prognosis factors to each composition of complexes. Indeed, one has to implement the further constraint that each subunit has to be contributed by one of several paralogous subunits. An original method previously developed by Xpop has already been successfully applied to WAVE complex data in breast cancer.

The developed models will be rendered user-friendly though a dedicated Rsoftware package.

This project can represent a significant step forward in precision medicine of the cutaneous melanoma.

(joint project with AP-HP Lariboisière and M3DISIM)

Two hundred million general anaesthesias are performed worldwide every year. Low blood pressure during anaesthesia is common and has been identified as a major factor in morbidity and mortality. These events require great reactivity in order to correct them as quickly as possible and impose constraints of reliability and reactivity to monitoring and treatment.

Recently, studies have demonstrated the usefulness of noradrelanine in preventing and treating intraoperative hypotension. The handling of this drug requires great vigilance with regard to the correct dosage. Currently, these drugs are administered manually by the healthcare staff in bolus and/or continuous infusion. This represents a heavy workload and suffers from a great deal of variability in order to find the right dosage for the desired effect on blood pressure.

The objective of this project is to automate the administration of noradrelanine with a closed-loop system that makes it possible to control the treatment in real time to an instantaneous blood pressure measurement.

(joint project with the InBio and IBIS inria teams and the MSC lab, UMR 7057)

Significant cell-to-cell heterogeneity is ubiquitously-observed in isogenic cell populations. Cells respond differently to a same stimulation. For example, accounting for such heterogeneity is essential to quantitatively understand why some bacteria survive antibiotic treatments, some cancer cells escape drug-induced suicide, stem cell do not differentiate, or some cells are not infected by pathogens.

The origins of the variability of biological processes and phenotypes are multifarious. Indeed, the observed heterogeneity of cell responses to a common stimulus can originate from differences in cell phenotypes (age, cell size, ribosome and transcription factor concentrations, etc), from spatio-temporal variations of the cell environments and from the intrinsic randomness of biochemical reactions. From systems and synthetic biology perspectives, understanding the exact contributions of these different sources of heterogeneity on the variability of cell responses is a central question.

The main ambition of this project is to propose a paradigm change in the quantitative modelling of cellular processes by shifting from mean-cell models to single-cell and population models. The main contribution of Xpop focuses on methodological developments for mixed-effects model identification in the context of growing cell populations.

(joint project with Lixoft)

Pharmacometrics involves the analysis and interpretation of data produced in pre-clinical and clinical trials. Population pharmacokinetics studies the variability in drug exposure for clinically safe and effective doses by focusing on identification of patient characteristics which significantly affect or are highly correlated with this variability. Disease progress modeling uses mathematical models to describe, explain, investigate and predict the changes in disease status as a function of time. A disease progress model incorporates functions describing natural disease progression and drug action.

The model based drug development (MBDD) approach establishes quantitative targets for each development step and optimizes the design of each study to meet the target. Optimizing study design requires simulations, which in turn require models. In order to arrive at a meaningful design, mechanisms need to be understood and correctly represented in the mathematical model. Furthermore, the model has to be predictive for future studies. This requirement precludes all purely empirical modeling; instead, models have to be mechanistic.

In particular, physiologically based pharmacokinetic models attempt to mathematically transcribe anatomical, physiological, physical, and chemical descriptions of phenomena involved in the ADME (Absorption - Distribution - Metabolism - Elimination) processes. A system of ordinary differential equations for the quantity of substance in each compartment involves parameters representing blood flow, pulmonary ventilation rate, organ volume, etc.

The ability to describe variability in pharmacometrics model is essential. The nonlinear mixed-effects modeling approach does this by combining the structural model component (the ODE system) with a statistical model, describing the distribution of the parameters between subjects and within subjects, as well as quantifying the unexplained or residual variability within subjects.

The objective of Xpop is to develop new methods for models defined by a very large ODE system, a large number of parameters and a large number of covariates.
Contributions of Xpop in this domain are mainly methodological and there is no privileged therapeutic application at this stage.

However, it is expected that these new methods will be implemented in software tools, including Monolix and Rpackages for practical use.

(joint project with the Molecular Chemistry Laboratory, LCM, of Ecole Polytechnique)

One of the main recent developments in analytical chemistry is the rapid democratization of high-resolution mass spectrometers. These instruments produce extremely complex mass spectra, which can include several hundred thousand ions when analyzing complex samples. The analysis of complex matrices (biological, agri-food, cosmetic, pharmaceutical, environmental, etc.) is precisely one of the major analytical challenges of this new century. Academic and industrial researchers are particularly interested in trying to quickly and effectively establish the chemical consequences of an event on a complex matrix. This may include, for example, searching for pesticide degradation products and metabolites in fruits and vegetables, photoproducts of active ingredients in a cosmetic emulsion exposed to UV rays or chlorination products of biocides in hospital effluents. The main difficulty of this type of analysis is based on the high spatial and temporal variability of the samples, which is in addition to the experimental uncertainties inherent in any measurement and requires a large number of samples and analyses to be carried out and computerized data processing (up to 16 million per mass spectrum).

A collaboration between Xpop and the Molecular Chemistry Laboratory (LCM) of the Ecole Polytechnique began in 2018. Our objective is to develop new methods for the statistical analysis of mass spectrometry data.

These methods are implemented in the SPIX software.

The Technical Achievement Award for 2020 is awarded to Eric Moulines, , for major contributions in statistical inference, in particular in hidden Markov chains and non-linear state models.

Created to address technological developments and data issues in the medical field, the “Numerical Innovation and Data Science for Healthcare” sponsorship program with Ecole polytechnique and Sanofi was inaugurated on November 13th. Marc Lavielle is co-leader of this program.

Fast Incremental Expectation Maximization (FIEM) is an iterative algorithm, based on the Expectation Maximization (EM) algorithm, which was introduced to design EM for the large scale learning framework by avoiding the full data set to be processed at each iteration. In this paper, we first recast this algorithm in the Stochastic Approximation (SA) within EM framework. Then, we provide non asymptotic convergence rates as a function of the batch size n and of the maximal number of iterations Kmax fixed by the user.

Antineoplastic agents are, for most of them, highly toxic drugs prepared at hospital following individualized prescription. To protect patients and healthcare workers, it is important to develop analytical tools able to identify and quantify such drugs on a wide concentration range. In this context, surface enhanced Raman spectroscopy (SERS) has been tested as a specific and sensitive technique. Despite the standardization of the nanoparticle synthesis, a polydispersity of nanoparticles in the suspension and a lack of reproducibility persist. This study focuses on the development of a new mathematical approach to deal with this nanoparticle polydispersity and its consequences on SERS signal variability through the feasibility of 5-fluorouracil (5FU) quantification using silver nanoparticles (AgNPs) and a handled Raman spectrophotometer. Variability has been maximized by synthetizing six different batches of AgNPs for an average size of 24.9 nm determined by transmission electron microscopy, with residual standard deviation of 17.0%. Regarding low performances of the standard multivariate data processing, an alternative approach based on the nearest neighbors were developed to quantify 5FU. By this approach, the predictive performance of the 5FU concentration was significantly improved. The mean absolute relative error (MARE) decreased from 16.8% with the traditional approach based on PLS regression to 6.30% with the nearest neighbors approach (p-value < 0.001). This study highlights the importance of developing mathematics adapted to SERS analysis which could be a step to overcome the spectral variability in SERS and thus participate in the development of this technique as an analytical tool in quality control to quantify molecules with good performances, particularly in the pharmaceutical field 6.

Missing attributes are ubiquitous in causal inference, as they are in most applied statistical work. In this paper, we consider various sets of assumptions under which causal inference is possible despite missing attributes and discuss corresponding approaches to average treatment effect estimation, including generalized propensity score methods and multiple imputation. Across an extensive simulation study, we show that no single method systematically out-performs others. We find, however, that doubly robust modifications of standard methods for average treatment effect estimation with missing data repeatedly perform better than their non-doubly robust baselines; for example, doubly robust generalized propensity score methods beat inverse-weighting with the generalized propensity score. This finding is reinforced in an analysis of an observations study on the effect on mortality of tranexamic acid administration among patients with traumatic brain injury in the context of critical care management. Here, doubly robust estimators recover confidence intervals that are consistent with evidence from randomized trials, whereas non-doubly robust estimators do not 9.

Missing values challenge data analysis because many supervised and unsupervised learning methods cannot be applied directly to incomplete data. Matrix completion based on low-rank assumptions are very powerful solution for dealing with missing values. However, existing methods do not consider the case of informative missing values which are widely encountered in practice. We propose matrix completion methods to recover Missing Not At Random (MNAR) data. Our first contribution is to suggest a model-based estimation strategy by modelling the missing mechanism distribution. An EM algorithm is then implemented, involving a Fast Iterative Soft-Thresholding Algorithm (FISTA). Our second contribution is to suggest a computationally efficient surrogate estimation by implicitly taking into account the joint distribution of the data and the missing mechanism: the data matrix is concatenated with the mask coding for the missing values ; a low-rank structure for exponential family is assumed on this new matrix, in order to encode links between variables and missing mechanisms. The methodology that has the great advantage of handling different missing value mechanisms is robust to model specification errors 11.

We developed a comprehensive framework for stability analysis of a broad class of commonly used continuous-and discrete-time filters for stochastic dynamic systems with nonlinear state dynamics and linear measurements under certain strong assumptions. The class of filters encompasses the extended and unscented Kalman filters and most other Gaussian assumed density filters and their numerical integration approximations. The stability results are in the form of time-uniform mean square bounds and exponential concentration inequalities for the filtering error. In contrast to existing results, it is not always necessary for the model to be exponentially stable or fully observed. We review three classes of models that can be rigorously shown to satisfy the stringent assumptions of the stability theorems. Numerical experiments using synthetic data validate the derived error bounds. 7.

High-resolution mass spectrometry-based non-targeted screening has a huge potential for applications in environmental sciences, engineering and regulation. However, it produces big data for which full appropriate processing is a real challenge; the development of processing software is the last building-block to enable large-scale use of this approach. Methods: A new software application, SPIX, has been developed to extract relevant information from high-resolution mass-spectrum datasets. Dealing with intrinsic sample variability and reducing operator subjectivity, it opens up opportunities and promising prospects in many areas of analytical chemistry.

Two features of the software are presented in the field of environmental analysis. An example illustrates how SPIX reveals photodegradation reactions in wastewater by fitting kinetic models to significant changes in ion abundance over time. A second example shows the ability of SPIX to detect photoproducts at trace amounts in river water, through comparison of datasets from samples taken before and after irradiation. Conclusions: SPIX has shown its ability to reveal relevant modifications between two series of big data sets, allowing for instance to study the consequences of a given event on a complex substrate. Most of alland this is to our knowledge the only software currently available allowing thatit can reveal and monitor any kind of reaction in all types of mixture 10.

Mixed-Effects Models of Intracellular Processes: Methods, Tools and Applications (MEMIP)

Coordinator: Gregory Batt (InBio Inria team)

Other partners: InBio and IBIS Inria teams, Laboratoire Matière et Systèmes Complexes (UMR 7057; CNRS and Paris Diderot Univ.)

Targeting Rac-dependent actin polymerization in cutaneous melanoma - Institut National du Cancer

Coordinator: Alexis Gautreau (Ecole Polytechnique)

Other partners: Laboratoire de Biochimie (Polytechnique), Institut Curie, INSERM.

diverse and varied

Marc Lavielle developed and maintains the learning platform Statistics in Action.
The purpose of this online learning platform is to show how statistics (and biostatistics) may be efficiently used in practice using R.
It is specifically geared towards teaching statistical modelling concepts and applications for self-study. Indeed, most of the available teaching material tends to be quite "static" while statistical modelling is very much subject to "learning by doing”.

Julie Josse (with Nicholas Tierney and Nathalie Vialaneix) developed and maintains the website R-miss-tastic,
A resource website on missing data.